% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, AŞ Message Board

  • loriskhireward loriskhireward Dec 6, 2011 12:24 PM Flag

    No, mark THIS post...

    Jla has continued to post on this msg board about the cost advantages of using vanco as first-line treatment for c-diff, despite clinical studies that showed there is basically no difference in results between the two drugs and now ECONOMIC studies that show it is profitable due to OVERALL costs of care. What he/she fails to address is the fact that Dificid REDUCES RECURRENCES of c-diff, which is why CMS (Medicare), insurance, hospitals and others will realize OVERALL cost savings by using it vs. the vanco treatment. Recurrences cost money, and the population most vulnerable to c-diff infection is GROWING by leaps & bounds over the next 20 or so years.

    So, with the patient population swelling, the clinical studies showing SUSTAINED clinical outcomes that are superior to vanco, and with the relief patients/families will get from REDUCING RECURRENCES, Dificid is on a path of success, imo. So, I am not worried about next quarter's earnings or revenue numbers - the market is exploding, and OPTR has the MOST SUCCESSFUL drug - period, end of story. If jla is able to convince his docs to continue to prescribe vanco for treatment of c-diff, those docs will have to answer when recurrences occur at a higher rate than if they had used Dificid, imo. Also, they will have to explain to the hospital why the same patients are re-admitting for the SAME CONDITION, nasty symptoms and DIAGNOSIS...